Uterine Fibroids Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids), By Treatment (Hormone Therapy, Androgens, Gonadotropin-Releasing Hormone Antagonists, Uterine Artery Embolization, Myomectomy, Hysterectomy), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 5.15 Billion
CAGR (2026-2031)	8.54%
Fastest Growing Segment	Hormone Therapy
Largest Market	North America
Market Size (2031)	USD 8.42 Billion

Market Overview

The Global Uterine Fibroids Treatment Market will grow from USD 5.15 Billion in 2025 to USD 8.42 Billion by 2031 at a 8.54% CAGR. The Global Uterine Fibroids Treatment Market centers on the therapeutic management of leiomyomas, which are benign monoclonal tumors arising from the smooth muscle cells of the uterus. The market is primarily propelled by the increasing demand for minimally invasive procedures that preserve fertility and reduce recovery times, such as uterine fibroid embolization and laparoscopic myomectomy. Furthermore, advancements in robotic surgical systems and the introduction of novel pharmacological therapies are expanding the treatment landscape, effectively supporting market growth by offering viable alternatives to traditional open surgeries.

Despite these advancements, a significant impediment to market expansion remains the persistent lack of patient awareness regarding alternative therapies and the historical over-reliance on major surgery. According to the Society of Interventional Radiology, in 2024, a survey revealed that 53% of women diagnosed with uterine fibroids were primarily offered a hysterectomy, while fewer than 20% were informed about less invasive options. This information gap restricts patient access to modern interventions and potentially stifles the growth of the minimally invasive treatment segment.

Key Market Drivers

Advancements in Minimally Invasive Surgical Techniques are fundamentally reshaping the market by offering effective alternatives to traditional hysterectomies. Patients are increasingly prioritizing uterine-sparing procedures that minimize recovery time and preserve fertility, driving the adoption of technologies such as radiofrequency ablation and hysteroscopic morcellation. This shift is fueling significant industry consolidation and investment in novel device platforms to meet the rising demand for incision-free interventions. For instance, according to Medical Product Outsourcing, January 2025, in the 'Hologic Completes $350M Deal for Gynesonics' report, Hologic acquired the developer of the Sonata System for approximately $350 million to expand its minimally invasive portfolio. Such high-value transactions underscore the growing commercial viability of modern surgical solutions as a preferred standard of care over major open surgeries.

Simultaneously, the Commercialization of Novel GnRH Antagonists is expanding the therapeutic landscape for patients seeking non-surgical management. These oral pharmacotherapies effectively control heavy menstrual bleeding and reduce fibroid volume, addressing a critical gap for women who are ineligible for or averse to surgery. The rapid uptake of these drugs highlights a robust market demand; according to Sumitomo Pharma, May 2025, in the 'Conference on FY2024 Financial Results', revenue for the treatment Myfembree increased by 32% year-over-year. This surge in pharmacological adoption is necessary to address the escalating global burden of the disease; according to Frontiers in Reproductive Health, September 2025, in the study 'The Epidemiology of Uterine Fibroids', the global age-standardized incidence rate of the condition rose to 250.93 per 100,000 women, confirming the widening patient pool requiring diverse treatment modalities.

Download Free Sample Report

Key Market Challenges

The persistent lack of patient awareness regarding alternative therapies, combined with a historical over-reliance on major surgery, constitutes a significant barrier to the growth of the Global Uterine Fibroids Treatment Market. When patients are insufficiently informed about minimally invasive options or novel pharmacological treatments, the adoption rate of these advanced medical technologies stagnates. This information asymmetry results in a continued preference for radical surgical interventions like hysterectomies, which effectively removes the patient from the addressable market for fertility-preserving devices and long-term management therapies. Consequently, manufacturers of non-surgical solutions face substantial difficulty in penetrating the market and achieving projected revenue targets, despite the clinical viability and recovery benefits of their products.

This impediment is clearly quantified by recent industry data highlighting the severity of the education gap. According to the Society of Interventional Radiology, in 2024, a survey indicated that 17% of women mistakenly believed that a hysterectomy was the only available treatment option for uterine fibroids. This misconception directly hampers market expansion by reducing the consumer demand for less invasive alternatives such as uterine fibroid embolization. Without a shift in patient understanding that drives demand for modern interventions, the market potential for emerging therapeutic segments will remain significantly underutilized.

Key Market Trends

Advancements in Image-Guided Non-Invasive Ablation Technologies are establishing a new therapeutic class distinct from traditional minimally invasive surgery. Unlike laparoscopic or transcervical methods that require physical entry into the body, technologies such as Magnetic Resonance-guided Focused Ultrasound (MRgFUS) utilize high-intensity sound waves to destroy fibroid tissue through intact skin. This completely non-invasive approach is gaining global traction due to its ability to preserve uterine integrity and eliminate surgical recovery time, appealing to patients seeking fertility-sparing options without the risks of instrumentation. According to the Focused Ultrasound Foundation, August 2025, in the '2025 State of the Field Report', uterine fibroids were identified as a leading indication among the more than one million patients treated with focused ultrasound technologies worldwide, highlighting the rapid clinical acceptance of this incision-less modality.

The Migration of Procedures to Outpatient and Ambulatory Surgical Settings is further reshaping the service delivery landscape, driven by payer incentives to reduce healthcare costs and the availability of office-ready devices. Healthcare providers are increasingly transitioning myomectomy and ablation procedures out of inpatient hospitals to ambulatory surgery centers (ASCs) and physician offices, a shift that necessitates equipment with smaller footprints and enhanced safety profiles. This structural change is evidenced by the robust commercial performance of devices specifically engineered for non-hospital environments. According to Hologic, Inc., November 2025, in the 'Financial Results for Fourth Quarter of Fiscal 2025' report, the company's surgical division revenue increased by 10.2%, a growth trajectory primarily attributed to the expanded utilization of the MyoSure and Sonata systems in outpatient gynecological facilities.

Segmental Insights

The Hormone Therapy segment represents the fastest-growing category within the Global Uterine Fibroids Treatment Market, driven by an increasing patient preference for non-surgical therapeutic alternatives. This rapid expansion is primarily catalyzed by the introduction and regulatory approval of novel oral Gonadotropin-releasing Hormone (GnRH) antagonists by key institutions such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These pharmacological advancements offer effective management of severe symptoms, including heavy menstrual bleeding, allowing women to avoid invasive procedures like hysterectomies. Consequently, the demand for these convenient, fertility-preserving options is accelerating market adoption globally.

Regional Insights

North America holds the leading position in the global uterine fibroids treatment market, driven by a high prevalence of the condition and a well-developed healthcare infrastructure. The region benefits from substantial healthcare spending and favorable reimbursement schemes that increase patient access to various surgical and non-surgical interventions. Additionally, the U.S. Food and Drug Administration (FDA) plays a critical role by evaluating and approving new drug applications and medical devices, which fosters clinical innovation. Strong patient advocacy groups also contribute by raising awareness, ensuring that women seek timely medical attention for fibroid management.

Recent Developments

• In May 2025, TiumBio Co., Ltd. and its partner Daewon Pharmaceutical announced the successful completion of a Phase 2 clinical trial for their investigational drug, Merigolix, targeting uterine fibroids. The study results demonstrated that the oral gonadotropin-releasing hormone antagonist achieved its primary efficacy and safety endpoints. Executives from the companies noted that the drug showed excellent therapeutic potential, reinforcing its viability as a promising new oral treatment. This positive breakthrough in their clinical research paved the way for accelerated development and future global market expansion, aiming to effectively address the significant burden that uterine fibroids place on women's health.
• In February 2025, Kissei Pharmaceutical Co., Ltd. submitted a New Drug Application to the Ministry of Health, Labour and Welfare in Japan for the approval of linzagolix. This application sought marketing authorization for the drug specifically as a treatment for uterine fibroids. Linzagolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist discovered by the company, had previously demonstrated potential in clinical studies. The submission marked a critical advancement in the company’s efforts to make this therapeutic option available to patients in Japan. The move followed the successful collection of clinical data confirming the drug's efficacy and safety in managing the condition.
• In October 2024, Hologic, Inc. entered into a definitive agreement to acquire Gynesonics, a medical device company specializing in minimally invasive solutions for women's health, for approximately $350 million. This strategic acquisition was designed to expand Hologic’s portfolio of uterine fibroid treatments by incorporating Gynesonics' Sonata System. The Sonata System utilizes an incision-free, transcervical approach that combines intrauterine ultrasound guidance with radiofrequency ablation. By integrating this technology, Hologic aimed to provide healthcare professionals with a broader range of options to treat symptomatic uterine fibroids effectively while offering patients a uterus-preserving alternative to more invasive surgical procedures.
• In January 2024, Sumitomo Pharma Canada, Inc. and Pfizer Canada ULC announced that their treatment, MYFEMBREE, had become available by prescription across Canada. This combination therapy was introduced for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The launch represented a significant milestone in the companies' ongoing collaboration to address critical unmet needs in women's health. The commercial availability followed Health Canada's regulatory approval and offered a new, non-invasive daily oral option for patients suffering from the debilitating symptoms of this chronic condition, aiming to improve their quality of life through effective medical management.

Key Market Players

• Gynesonics Inc.
• Medtronic Plc.
• Boston Scientific Corporation
• Karl Storz Gmbh
• Pfizer Inc.
• Abbvie Inc.
• Richard Wolf GmbH
• CooperSurgical Inc.
• Olympus Corporation
• Myovant Sciences GmbH

By Type	By Treatment	By End-User	By Region
Subserosal Fibroids Intramural Fibroids Submucosal Fibroids Pedunculated Fibroids	Hormone Therapy Androgens Gonadotropin-Releasing Hormone Antagonists Uterine Artery Embolization Myomectomy Hysterectomy	Hospitals & Clinics Ambulatory Surgical Centers Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Uterine Fibroids Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Uterine Fibroids Treatment Market , By Type:

• Subserosal Fibroids
• Intramural Fibroids
• Submucosal Fibroids
• Pedunculated Fibroids

• Uterine Fibroids Treatment Market , By Treatment:

• Hormone Therapy
• Androgens
• Gonadotropin-Releasing Hormone Antagonists
• Uterine Artery Embolization
• Myomectomy
• Hysterectomy

• Uterine Fibroids Treatment Market , By End-User:

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others

• Uterine Fibroids Treatment Market , By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE